Oramed Pharmaceuticals develops pharmaceutical solutions for diabetes treatment and orally ingestible capsules for polypeptide delivery. Products include oral insulin capsule ORMD-0801, in phase III clinical trials for diabetes and NASH treatment. Other products are in phase II trial for type 2 diabetes treatment. The company also licenses COVID-19 and novel coronavirus vaccines. Incorporated in 2002, headquartered in New York.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 7.1 |